TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
2.130
-0.090 (-4.05%)
At close: Apr 28, 2026, 4:00 PM EDT
2.190
+0.060 (2.82%)
Pre-market: Apr 29, 2026, 4:48 AM EDT
TuHURA Biosciences Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for TuHURA Biosciences stock have an average target of 9.50, with a low estimate of 9.00 and a high estimate of 10. The average target predicts an increase of 346.01% from the current stock price of 2.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TuHURA Biosciences stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Initiates $9 | Buy | Initiates | $9 | +322.54% | Apr 27, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +369.48% | Feb 3, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 → $10 | Strong Buy | Reiterates | $12 → $10 | +369.48% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +463.38% | May 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $12 | Strong Buy | Maintains | $13 → $12 | +463.38% | Apr 3, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
23.02M
EPS This Year
-0.51
from -0.63
EPS Next Year
-0.59
from -0.51
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 71.1M | ||||||
| Avg | n/a | 23.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.47 | -0.61 | ||||||
| Avg | -0.51 | -0.59 | ||||||
| Low | -0.54 | -0.57 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.